| HOME >> BIOLOGY >> TECHNOLOGY |
September 30, 2008 September 30, 2007
------------------- -------------------
GAAP "Adjusted" GAAP "Adjusted"
------------------- -------------------
Income (Numerator):
Net income for basic and
diluted EPS $3,235 $3,761 $2,331 $3,716
======= ======= ======= =======
Shares (Denominator):
Weighted-average shares
for basic EPS 1,075 1,075 1,127 1,127
Effect of dilutive
securities 4 3(*) 6 4(*)
------- ------- ------- -------
Weighted-average shares
for diluted EPS 1,079 1,078 1,133 1,131
======= ======= ======= =======
Diluted earnings per share $3.00 $3.49 $2.06 $3.29
======= ======= ======= =======
(*) Dilutive securities used to compute "Adjusted" diluted earnings per
share for the three and nine months ended September 30, 2008 and 2007
were computed exclusive of the methodology used to determine dilutive
securities under SFAS No. 123R.
Amgen Inc.
Product Sales Detail by Product and Geographic Region
(In millions)
(Unaudited)
Three months ended Nine months ended
September 30, September 30,
------------------ -----------------
2008 2007
'/>"/>
| SOURCE Amgen Copyright©2008 PR Newswire. All rights reserved |